Роль фактора некроза опухоли альфа (ФНО-α) в развитии обменных нарушений и атеросклероза и влияние на них ингибиторов ФНО-α у больных ревматическими заболеваниями
https://doi.org/10.14412/1995-4484-2009-461
Аннотация
Несмотря на различия в этиологии и патогенезе, разнообразие клинических проявлений ревматических заболеваний (РЗ), в основе большинства из них лежит хроническое воспаление. Важная роль в его развитии отводится вырабатываемым при иммунных реакциях преимущественно макрофагами и Т-лимфоцитами цитокинам, многие из которых обладают провоспалительным действием и, кроме того, участвуют в регуляции обменных процессов. Большое значение в формировании воспаления, имеющего ряд общих иммунных механизмов при некоторых наиболее часто встречаемых РЗ (ревматоидном артрите (РА), псориатическом артрите, подагре), принадлежит фактору некроза опухоли-α (ФНО-α) [1-4]. Именно с гиперпродукцией цитокинов, в том числе ФНО-α, связано увеличение риска развития атеросклероза и ассоциируемых с ним сосудистых осложнений [5].
Список литературы
1. <div><p>Feldman M., Brenan F.M., Maini R.N. Role of cytokines in rheumatoid arthritis. Ann. Rev. Immunol., 1996, 14, 397-440.</p><p>Насонов Е.Л. Фактор некроза опухоли-α – новая мишень для противовоспалительной терапии ревматоидного артрита. Русс. мед. жур., 2000, 17, 718-22.</p><p>Khan M.A. Update on psoriasis as it relates to spondyloarthropathies. EULAR, 2001. Ann. Rheum. Dis. 2001, 60, suppl.1, SP0033.</p><p>Насонов Е.Л., Насонова В.А., Барскова В.Г. Механизмы развития подагрического воспаления. Тер. архив, 2006, 6, 74-7.</p><p>Насонов Е.Л. Иммунологические маркеры атероклероза. Тер. архив, 2002, 5, 80-5.</p><p>Aggarwal B.B. Tumor necrosis factors receptor associated signalling molecules and their role in activation of apoptosis. JNK and NF-KB. Ann. Rheum. Dis., 2000, 59(1), i6-i16.</p><p>Qian H., Hausman D.B., Compton M.M. et al. TNF- alpha induces and insulin inhibits caspase 3-depen- dent adipocyte apoptosis. Biochem. Biophys. Res. Commun., 2001, 284, 1176-83.</p><p>Cornelius P., Lee M.P., Marlowe M., Pekala P.H. Monokine regulation of glucose transporter mRNA in L6 myotubes. Biochem. Biophys. Res. Commun., 1989, 165, 429-36.</p><p>Stephens J.M., Pekala P.H. Transcriptional repression of the GLUT4 and C/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. J. Biol. Chem., 1991, 266, 21839-45.</p><p>Lang C.H., Dobrescu C., Bagby G.J. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology, 1992, 130, 43-52.</p><p>Beutler B., Cerami A. The biology of cachectin/TNF-a primary mediator of the host response. Ann. Rev. Immunol., 1989, 7, 625-55.</p><p>Grunfeld C., Feingold K.R. The metabolic effects of tumor necrosis factor and other cytokines. Biotherapy, 1991, 3, 143-50.</p><p>Van Der Poll T., Romin J.A., Endert E. et al. Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. Am. J. Physiol., 1991, 261, E457-E465.</p><p>McCall J.L., Tuckey J.A., Parry B.R. Serum tumour necrosis factor alpha and insulin resistance in gastrointestinal cancer. Br. J. Surg., 1992, 79, 1361-63.</p><p>Marano M.A., Moldawer L.L., Fong Y. et al. Cachectin/TNF production in experimental burns and Pseudomonas infection. Arch. Surg., 1988, 123, 1383- 6.</p><p>Youn Y.K., LaLonde C., Demling, R. The role of mediators in the response to thermal injury. World J. Surg., 1992, 16, 30-6.</p><p>Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science, 1993, 259, 87-91.</p><p>Sethi J.K., Hotamisligil G.S. The role of TNF alpha in adipocyte metabolism. Semin. Cell Dev. Biol., 1999, 10, 19-29.</p><p>Uysal K.T., Wiesbrock S.M., Marino M.W., Hotamisligil G.S. Protection from obesityinduced insu- lin resistance in mice lacking TNF-alpha function. Nature, 1997, 389, 610-4.</p><p>Kern P.A., Ranganathan S., Li C.,et al. L., Adipose tissue tumor necrosis factor and interleukin-6 expres- sion in human obesity and insulin resistance. Am. J. Physiol. Endocrinol. Metab., 2001, 280, 745-51.</p><p>Lyon C.J., Law R.E., Hsueh W.A. Minireview: Adiposity, Inflammation, and Atherogenesis. Endocrinology, 2003, 144(6), 2195-200.</p><p>Rask-Madsen C., Domínguez H., Ihlemann N. et al. Tumor Necrosis Factor-α Inhibits Insulin’s Stimulating Effect on Glucose Uptake and Endothelium-Dependent Vasodilation in Humans. Circulation, 2003, 108, 1815-21.</p><p>Hotamasligil G.S. Molecular mechanism of insulin resistance and the role of the adipocyte. Int. J. Obes., 2000, 24(suppl. 4), 23-7.</p><p>Kern P.A., Saghizadeh M., Ong J.M. et al. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J. Clin. Invest., 1995, 95, 2111-9.</p><p>Memon R.A., Feingold K.R., Moser A.H., et al. Regulation of fatty acid transport protein and fatty acid translocase mRNA levels by endotoxin and cytokines. Am. J. Physiol., 1998a, 274, E210-E217.</p><p>Насонов Е.Л. Иммунологические маркеры атеросклероза. М., «Литтера», 2004.</p><p>Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation, 2002, 105, 1135-43.</p><p>Chia S., Quadan M., Newton R. et al. Intra-arterial tumor necrosis factor-alpha impairs endothelial- dependent dilatation in humans. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 695-701.</p><p>Picchi A., Gao X., Belmadani S. Tumor Necrosis Factor-α Induces Endothelial Dysfunction in the Prediabetic Metabolic Syndrome. Circul. Res., 2006, 99, 69-77.</p><p>Spranger J., Kroke A., Mohlig M. et al. Inflammatory Cytokines and the Risk to Develop Type 2 Diabetes. Results of the Prospective Population-Based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes, 2003, 52, 812-7.</p><p>Schram M.T., Chaturvedi N., Schalkwijk C.et al. Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes. Diabetes Care, 2003, 26(7), 2165-73.</p><p>Lee L.-F., Xu B., Michie S.A. et al. The role of TNF-α in the pathogenesis of type 1 diabetes in the nonobese diabetic mouse: Analysis of dendritic cell maturation. PNAS, 2005, 102(44), 15995-16000.</p><p>Weisberg S.P., McCann D., Desai M. et al. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest., 2003, 112, 1796-1808.</p><p>Knobler H., Zhornicky T., Sandler A. et al. Tumor necrosis factor-alphainduced insulin resistance may mediate the hepatitis C virus-diabetes association. Am. J. Gastroenterol., 2003, 98, 2751-6.</p><p>Bahtiyar G., Shin J.J., Aytaman A., et al. Association of diabetes and hepatitis C infection: epidemiologic evi- dence and pathophysiologic insights. Curr. Diab. Rep., 2004, 4, 194-8.</p><p>Rana J.S., Mittleman M.A., Sheikh J. et al. Chronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in women. Diabetes Care., 2004, 27, 2478-84.</p><p>Iribarren C., Tolstykh, I.V., Eisner M.D. Are patients with asthma at increased risk of coronary heart disease? Int. J. Epidemiol., 2004, 33, 743-8.</p><p>Sattar N., McCarey D.W., Capell H., McInnes I.B. Explaining how “highgrade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation, 2003, 108, 2957-63.</p><p>Ильиных Е.В., Барскова В.Г., Александрова Е.Н. и др. С-реактивный белок при подагрическом артрите: связь с кардиоваскулярной патологией. Научно-практич. ревматол., 2005, 6, 33-7.</p><p>Барскова В.Г., Ильиных Е.В., Елисеев М.С. и др. Кардиоваскулярный риск у больных подагрой. Ожирение и метаболизм, 2006, 3(8), 40-4.</p><p>Shoelson S. Invited comment on W. Ebstein: on the therapy of diabetes mellitus, in particular on the application of sodium salicylate. J. Mol. Med., 2002, 80, 618-9.</p><p>Reid J., Macdougall A.I. Andrews M.M. On the efficacy of salicylate in treating diabetes mellitus. Br. Med. J., 1957, 2, 1071-4. 71</p><p>Hundal R.S., Petersen K.F., Mayerson A.B. et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J. Clin. Invest., 2002, 109, 1321-6.</p><p>Shoelson S.E., Lee J., Yuan M. Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance. Int. J. Obes. Relat. Metab. Disord., 2003, 27(suppl. 3), S49-S52.</p><p>Brennan F.M., Maini R.N., Feldmann M. TNF α-a pivotal role in rheumatoid arthritis? Br. J. Rheumatol., 1992, 31, 293-8.</p><p>Насонов Е.Л. Моноклональные антитела к фактору некроза опухоли-α в ревматологии. Русс. мед. жур., 2003, 7, 390-4.</p><p>Lichtenstein G.R., Yan S., Bala M., et. al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterology, 2005, 128, 862-9.</p><p>Rutgeerts P., Sandborn W., Feagan B. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med., 2005, 353(23), 2462-76.</p><p>Booth A., Harper L., Hammad T. et al. Prospective study of TNF-α blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J. Amer. Soc. Nephrol., 2004, 15, 717- 21.</p><p>Fedorova A.A., Kudaeva F.M., Barskova V.G., Nassonova V.A. Treatment with TNF-alpha inhibitor infliximab (Remicade®) chronic tophaceous gout with chronic renal failure and resistance to glucocorticoid therapy. Abstracts. Ann. Rheum. Dis., 2006, 65(suppl II), 432.</p><p>Ofei F., Hurel S., Newkirk J., Sopwith M., Taylor R. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes, 1996, 45(7), 881-5.</p><p>Gonzalez-Gay M.A., De Matias J.M., Gonzalez-Juanatey C. et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin. Exp. Rheumatol., 2006, 24(1), 83-6.</p><p>Kiortsis D.N., Mavridis A.K., Vasakos S. et al. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann. Rheum. Dis., 2005, 64(5), 765-6.</p><p>Oguz F.M., Oguz A., Uzunlulu M. The effect of infliximab treatment on insulin resistance in patients with rheumatoid arthritis. Acta. Clin. Belg., 2007, 62(4), 218-22.</p><p>Hürlimann D., Forster A., Noll G. Anti–tumor necrosis factor-α treatment improves endothelial function in patients with rheumatoid arthritis. Circulation, 2002, 106, 2184-7.</p><p>Macías I., García-Pérez S., Ruiz-Tudela M. Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis. 72 J. Rheumatol., 2005, 32(11), 2102-8.</p><p>Gonzalez-Gay M.A., Garcia-Unzueta M.T., De Matias J.M. et al. Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with athero- genesis in patients with rheumatoid arthritis. Clin. Exp. Rheumatol., 2006, 24(4), 373-9.</p><p>Klimiuk P.A., Sierakowski S., Domyslawska I., Chwiecko J. Regulation of serum chemokines following infliximab therapy in patients with rheumatoid arthri- tis. Clin. Exp. Rheumatol., 2006, 24(5), 529-33.</p><p>Booth A.D., Jayne D.R.W., Kharbanda R.K. Infliximab improves endothelial dysfunction in Systemic Vasculitis: a model of vascular inflammation. Circulation, 2004, 109, 1718-23.</p><p>Komai N., Morita Y., Sakuta T. et al. Anti-tumor necrosis factor therapy increases serum adiponec- tin levels with the improvement of endothelial dys- function in patients with rheumatoid arthritis. Mod. Rheumatol., 2007, 17(5), 385-90.</p><p>Westermann D., Van Linthout S., Dhayat S. et al. Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol., 2007, 102(6), 500-7.</p><p>Nishida S., Okada Y., Nawata M. et al. Induction of hyperadiponectinemia following long-term treatment of patients with rheumatoid arthritis with infliximab (IFX), an anti-TNF-alpha antibody. Endocrine J., 2008, 55(1), 213-6.</p><p>Vis M., Nurmohamed M.T., Wolbink G. et al. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J. Rheumatol., 2005, 32(2), 252-5.</p><p>Seriolo B., Paolino S., Sulli A. et al. Effects of anti- TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann. N. Y. Acad. Sci., 2006, 1069, 414-9.</p><p>Popa C., van den Hoogen F.H., Radstake T.R. Modulation of lipoprotein plasma concentrations dur- ing long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann. Rheum. Dis., 2007, 66(11), 1503-7.</p><p>Dahlqvist S.R., Engstrand S., Berglin E., Johnson O. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term inflix- imab therapy. Scand. J. Rheumatol., 2006, 35(2), 107-11.</p><p>Kiortsis D.N., Mavridis A.K., Filippatos T.D. et al. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J. Rheumatol., 2006, 33(5), 921-3.</p><p>Jacobsson L.T., Turesson C., Gülfe A. et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J. Rheumatol., 2005, 32(7), 1213-8.</p><p>Naranjo A., Sokka T., Descalzo M.A. et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthr. Res. Ther., 2008, 10(2), R30.</p><p>Larsen C.M., Faulenbach M., Vaag A. et al. Interleukin-1–receptor antagonistin type 2 diabetes mellitus. N. Engl. J. Med., 2007, 356, 1517-6.</p></div><br />
Рецензия
Для цитирования:
Eliseev M.S., Барскова В.Г., Насонов Е.Л. Роль фактора некроза опухоли альфа (ФНО-α) в развитии обменных нарушений и атеросклероза и влияние на них ингибиторов ФНО-α у больных ревматическими заболеваниями. Научно-практическая ревматология. 2009;47(2):67-72. https://doi.org/10.14412/1995-4484-2009-461
For citation:
Eliseev M.S., Barskova V.G., Nasonov E.L. Tumor necrosis factor α (TNFα) role in the development of metabolic disturbances and atherosclerosis and TNFα antagonists influence on them in patients with rheumatic diseases. Rheumatology Science and Practice. 2009;47(2):67-72. (In Russ.) https://doi.org/10.14412/1995-4484-2009-461
Просмотров: 2312
Послать статью по эл. почте 